Beam Therapeutics (MEX:BEAM) Institutional Ownership: 75.66% (As of Jul. 12, 2026)


MEX:BEAM Beam Therapeutics Inc MEX:BEAM
69 GF Score
Price MXN655.00
GF Value MXN571.91
Valuation Fairly Valued
! 6 Warning Signs
View Full Analysis

What is Beam Therapeutics Institutional Ownership?

Beam Therapeutics MEX:BEAM 69 Institutional Ownership is 75.66% as of Jul. 12, 2026. GuruFocus rates MEX:BEAM with a GF Score™ of 69/100 and a GF Value™ of MXN571.91 (Fairly Valued). The stock has 6 warning signs investors should review.

Institutional ownership is the percentage of shares that are owned by institutions out of the total shares outstanding. As of today, Beam Therapeutics's institutional ownership is 75.66%.

Insider Ownership is the percentage of shares that are owned by company insiders relative to the total shares outstanding. As of today, Beam Therapeutics's Insider Ownership is 0.00%.

Float Percentage Of Total Shares Outstanding is the percentage of float shares relative to the total shares outstanding. As of today, Beam Therapeutics's Float Percentage Of Total Shares Outstanding is 64.54%.

Beam Therapeutics Institutional Ownership Historical Data

* Premium members only.

The historical data trend for Beam Therapeutics's Institutional Ownership can be seen below:

* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.

Beam Therapeutics Institutional Ownership Chart

Beam Therapeutics Historical Data

The historical data trend for Beam Therapeutics can be seen below:

2025-09-30 2025-10-31 2025-11-30 2025-12-31 2026-01-31 2026-02-28 2026-03-31 2026-04-30 2026-05-31 2026-06-30
Institutional Ownership 74.02 74.49 76.75 78.49 78.35 78.50 76.71 74.85 74.80 75.66
MEX:BEAM
69GF Score
Beam Therapeutics Inc MEX:BEAM
Institutional Ownership is just one metric. See GF Score™, valuation, warning signs, and more.
View Full Analysis

Beam Therapeutics Institutional Ownership Calculation

The percentage of shares that are owned by institutions out of the total shares outstanding.

What does a Institutional Ownership of 75.66% mean?
Beam Therapeutics (MEX:BEAM) has a Institutional Ownership of 75.66% as of Jul. 12, 2026. Institutional ownership equals the percent of shares owned by financial institutions relative to total shares. View historical data on Beam Therapeutics and its competitors.
Is Beam Therapeutics' Institutional Ownership too high?
Beam Therapeutics' current Institutional Ownership is 75.66%. Overall, Beam Therapeutics has a GF Score™ of 69/100 and is considered Fairly Valued, reflecting its overall financial health beyond just this single metric.
How does Beam Therapeutics' Institutional Ownership compare to ELVN and IDYA?
Beam Therapeutics' Institutional Ownership of 75.66% can be compared against companies in the Biotechnology industry. See the competitive comparison table and distribution chart on this page for a detailed peer-by-peer breakdown.
What is a good Institutional Ownership for a Biotechnology company?
A good Institutional Ownership depends on the Biotechnology industry context. However, Institutional Ownership should not be evaluated in isolation — investors should consider it alongside profitability, growth, and financial strength metrics. Use the industry distribution chart on this page to see where any company falls relative to its peers.
What does a high Institutional Ownership mean?
A high Institutional Ownership can signal that a stock is expensive relative to its fundamentals. Institutional ownership equals the percent of shares owned by financial institutions relative to total shares. View historical data on Beam Therapeutics and its competitors. Beam Therapeutics's current Institutional Ownership is 75.66%. However, context matters — high-growth companies often justify higher valuations. Always evaluate alongside other metrics like GF Score™ and GF Value™.
Is Beam Therapeutics stock overvalued right now?
Based on GuruFocus' analysis, Beam Therapeutics (MEX:BEAM) is currently considered Fairly Valued. The stock's GF Value™ is MXN571.91, compared to a current price of MXN655.00 — trading 14.5% above its estimated fair value. The current Institutional Ownership is 75.66%. Beam Therapeutics' overall GF Score™ is 69/100 with 6 warning signs to review. Investors should evaluate multiple metrics — including profitability, growth, and financial strength — before making a decision.
How is Institutional Ownership calculated?
Institutional Ownership is calculated from a company's financial statements. For Beam Therapeutics (MEX:BEAM), the current Institutional Ownership is 75.66% as of Jul. 12, 2026. GuruFocus calculates this using data sourced from SEC filings and annual reports. See the calculation section and 30-year financial data on this page for the full breakdown.

Is Beam Therapeutics (MEX:BEAM) Overvalued in 2026?

Based on GuruFocus' analysis, Beam Therapeutics stock appears to be overvalued. The current stock price of MXN655.00 is trading 14.5% above its estimated GF Value™ of MXN571.91. GuruFocus considers Beam Therapeutics to be Fairly Valued.

Key valuation signals for MEX:BEAM:

  • Institutional Ownership: 75.66%
  • GF Value™: MXN571.91 vs. price of MXN655.00 (14.5% above fair value)
  • GF Score™: 69/100 with 6 warning signs

No single metric tells the full story. See the MEX:BEAM stock analysis page for a complete view including 30-year financials, guru trades, and insider activity.

Beam Therapeutics Business Description

Other Exchanges BEAM:USA
Address 238 Main Street, Cambridge, MA, USA, 02142
Beam Therapeutics Inc is a biotechnology company committed to creating a new class of precision genetic medicines based on its proprietary base editing technology, with a vision of providing lifelong cures to patients suffering from serious diseases. The company is focused on its programs in the hematology and genetic disease portfolios, which comprise different product candidates in its pipeline, such as BEAM-101, which is being developed to target Sickle Cell Disease, BEAM-302, a liver-targeting lipid nanoparticle, being developed to target Alpha-1 antitrypsin deficiency, and other drug candidates including BEAM-302, BEAM-103 & 104. The company operates and manages its business in one operating segment, United States.
69GF Score

Get the complete analysis for MEX:BEAM

Institutional Ownership is just one metric. See GF Value™, 30-year financials, guru trades, warning signs, and more.

MXN655.00
Price
MXN571.91
GF Value